FYAVOLV

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FYAVOLV (FYAVOLV).

How it works

FYAVOLV is a monoclonal antibody that targets and inhibits the activity of a specific protein involved in tumor growth and immune evasion. It binds to the extracellular domain of the target receptor, preventing ligand binding and downstream signaling, thereby inhibiting cell proliferation and inducing apoptosis in cancer cells.

What the body does with it

Metabolism	FYAVOLV is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways. No specific metabolic enzymes are involved. The elimination is through catabolism and renal excretion of metabolites.
Excretion	Primarily renal excretion of unchanged drug (approximately 60-70% of the dose) and hepatic metabolism with biliary/fecal elimination (30-40%).
Half-life	Terminal elimination half-life is 20-30 hours in patients with normal renal function, allowing once-daily dosing. Half-life is prolonged in renal impairment.
Protein binding	99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.2 L/kg, indicating limited distribution into tissues and primarily confined to the intravascular space.
Bioavailability	Oral bioavailability is 50-70% due to first-pass metabolism. Absolute bioavailability data for intravenous route is 100%.
Onset of Action	Oral: 2-4 hours to peak plasma concentration; therapeutic effect observed within 1-2 weeks. Intravenous: Immediate (minutes) for hemodynamic effects.
Duration of Action	Duration of action is 24 hours for primary pharmacodynamic effects, supporting once-daily dosing. Clinical effect may persist beyond 24 hours due to slow elimination.

Classification & Brands

Dosing & administration

300 mg orally once daily with food.

Dosage form	TABLET
Renal impairment	eGFR ≥50 mL/min: no adjustment required; eGFR 30–49 mL/min: consider 200 mg once daily; eGFR <30 mL/min (not on dialysis): 200 mg every other day; hemodialysis: 200 mg after dialysis on dialysis days.
Liver impairment	Child-Pugh A: no adjustment necessary; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment recommended based on age alone; monitor renal function and adjust per renal guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FYAVOLV (FYAVOLV).

Breastfeeding	Excretion into breast milk is unknown; M/P ratio not established. Potential for serious adverse reactions in nursing infants; therefore, breastfeeding is contraindicated during therapy.
Teratogenic Risk	First trimester: Risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and orofacial clefts. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus, and persistent pulmonary hypertension of the newborn. Avoid use in pregnancy unless no alternative.

Warnings & precautions

■ FDA Black Box Warning

WARNING: SERIOUS INFECTIONS, INCLUDING FATAL INFECTIONS, HAVE BEEN REPORTED IN PATIENTS RECEIVING FYAVOLV. PATIENTS SHOULD BE MONITORED FOR SIGNS AND SYMPTOMS OF INFECTION DURING AND AFTER TREATMENT. DISCONTINUE FYAVOLV FOR SEVERE OR LIFE-THREATENING INFECTIONS.

Side Effect Profile

Serious Effects

Absolute Contraindications

History of severe hypersensitivity reaction to FYAVOLV or any of its excipients; active severe infection; concomitant use with live vaccines.

Clinical Precautions

Precautions

Risk of serious infections, including opportunistic infections; infusion-related reactions; immune-mediated adverse reactions (e.g., pneumonitis, colitis, hepatitis, endocrinopathies); embryo-fetal toxicity; immunogenicity.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FYAVOLV

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FYAVOLV (FYAVOLV).

How it works

What the body does with it

Metabolism	FYAVOLV is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways. No specific metabolic enzymes are involved. The elimination is through catabolism and renal excretion of metabolites.
Excretion	Primarily renal excretion of unchanged drug (approximately 60-70% of the dose) and hepatic metabolism with biliary/fecal elimination (30-40%).
Half-life	Terminal elimination half-life is 20-30 hours in patients with normal renal function, allowing once-daily dosing. Half-life is prolonged in renal impairment.
Protein binding	99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.2 L/kg, indicating limited distribution into tissues and primarily confined to the intravascular space.
Bioavailability	Oral bioavailability is 50-70% due to first-pass metabolism. Absolute bioavailability data for intravenous route is 100%.
Onset of Action	Oral: 2-4 hours to peak plasma concentration; therapeutic effect observed within 1-2 weeks. Intravenous: Immediate (minutes) for hemodynamic effects.
Duration of Action	Duration of action is 24 hours for primary pharmacodynamic effects, supporting once-daily dosing. Clinical effect may persist beyond 24 hours due to slow elimination.

Classification & Brands

Dosing & administration

300 mg orally once daily with food.

Dosage form	TABLET
Renal impairment	eGFR ≥50 mL/min: no adjustment required; eGFR 30–49 mL/min: consider 200 mg once daily; eGFR <30 mL/min (not on dialysis): 200 mg every other day; hemodialysis: 200 mg after dialysis on dialysis days.
Liver impairment	Child-Pugh A: no adjustment necessary; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment recommended based on age alone; monitor renal function and adjust per renal guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FYAVOLV (FYAVOLV).

Breastfeeding	Excretion into breast milk is unknown; M/P ratio not established. Potential for serious adverse reactions in nursing infants; therefore, breastfeeding is contraindicated during therapy.
Teratogenic Risk	First trimester: Risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and orofacial clefts. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus, and persistent pulmonary hypertension of the newborn. Avoid use in pregnancy unless no alternative.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

History of severe hypersensitivity reaction to FYAVOLV or any of its excipients; active severe infection; concomitant use with live vaccines.